Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients
2017 · European Journal of Cancer · 46 citations
https://doi.org/10.1016/j.ejca.2017.05.010